Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.79% | 5.57% | 6.46% | 8.12% | 1.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.79% | 5.57% | 6.46% | 8.12% | 1.54% |
| Cost of Revenue | -10.99% | 3.98% | 7.42% | 22.80% | 9.99% |
| Gross Profit | 13.27% | 7.01% | 5.44% | -2.28% | -5.01% |
| SG&A Expenses | 8.95% | 16.89% | 18.52% | 40.94% | 18.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.27% | 10.87% | 10.93% | 24.31% | 10.29% |
| Operating Income | 8.37% | -33.66% | -23.29% | -287.34% | -116.38% |
| Income Before Tax | 11.08% | -71.85% | -54.21% | -139.05% | -5,048.41% |
| Income Tax Expenses | 64.60% | 143.20% | 997.79% | 5,788.97% | -192.22% |
| Earnings from Continuing Operations | -11.30% | -117.77% | -65.46% | -557.08% | -682.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.30% | -117.77% | -65.46% | -557.08% | -682.15% |
| EBIT | 8.37% | -33.66% | -23.29% | -287.34% | -116.38% |
| EBITDA | 13.25% | -39.58% | -26.70% | -176.40% | -203.46% |
| EPS Basic | -9.09% | -113.41% | -65.09% | -560.37% | -695.83% |
| Normalized Basic EPS | 13.12% | -85.63% | -53.73% | -139.40% | -5,542.86% |
| EPS Diluted | -9.09% | -113.41% | -66.67% | -582.33% | -695.83% |
| Normalized Diluted EPS | 13.12% | -85.63% | -53.73% | -139.40% | -5,542.86% |
| Average Basic Shares Outstanding | 2.20% | 1.99% | 0.28% | -0.71% | -2.64% |
| Average Diluted Shares Outstanding | 2.20% | 1.99% | 0.28% | -0.71% | -3.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |